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INTRODUCTION:  Tumoral  calcinosis  (TC) is a rare  disorder  deﬁned  by  hyperphosphatemia  and  ectopic
calciﬁcations  in  various  locations.  The  most  common  form  of  TC is  associated  with  disorders  such as
renal  insufﬁciency,  hyperparathyroidism,  or hypervitaminosis  D. The  primary  (hereditary)  TC  is caused
by inactivating  mutations  in either  the  ﬁbroblast  growth  factor  23  (FGF23),  the  GalNAc  transferase  3
(GALNT3)  or  the KLOTHO  (KL)  gene.
PRESENTATION  OF  CASE:  We  report  here  a  case  of secondary  TC  in end-stage  renal  disease.  The  patient
was  on regular  hemodialysis  and  presented  with  severe  painful  soft-tissue  calciﬁcations  around  her left
hip and shoulder  that  had  been  increasing  over  the  last  two  years.  Initially,  she  was  treated  with  dietary
phosphate  restriction  and  phosphate  binders.  Because  of  high  phosphate  blood  levels, which  were  not
yet  managed  with  dialysis  and medical  therapy,  a subtotal  parathyroidectomy  (sP)  was  performed.  This
approach  demonstrated  signiﬁcant  response.  Three  months  after  surgery  a rapid  regression  of the  tumors
was observed.
DISSCUSION:  Regardless  of the  etiology,  the  two  types  of TC  do  not  differ  in their  radiologic  or histopatho-
logic  presentations  but need  to  be diagnosed  correctly  to  initiate  targeted  and effective  treatment.
Considering  the primary  TC,  primary  treatment  is  early  and  complete  surgical  excision.  In case  of  sec-
ondary  TC  surgical  excision  of  the  tumoral  masses  should  be  avoid  because  of  extensive  complications.
These  patients  beneﬁt  from  sP.
CONCLUSION:  After  initial  conservative  therapy  chronic  kidney  disease  patients  with  TC  might  beneﬁt
from  sP  to avoid  prolonged  suffering  and  potential  mutilations.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
TC is a rare disorder with disturbance in the phosphate
etabolism deﬁned by hyperphosphatemia and ectopic calciﬁ-
ation in various locations [1,2]. As originally described, TC is
 primary or hereditary entity caused by autosomal recessive
utations in three genes involving phosphate metabolism: FGF23,
ALNT3 and KL [3]. Mutations in FGF23 or GALNT3 genes result either
Abbreviations: TC, tumoral calcinosis; sP, subtotal parathyroidectomy; FGF23,
broblast growth factor 23; GALNT3, GalNAc transferase 3; KL, KLOTHO; THR, total
ip  replacement; ROM, range of motion; CRP, C reactive protein; WBC, white blood
ells; PTH, parathyroid hormone; CT, computed tomography.
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in inadequate intact FGF23 or limited secretion. Mutations in KL
gene effect resistance to FGF23 activity at the ﬁbroblast growth fac-
tor receptor/-Klotho complex [4]. The limitation in FGF23 activity
induces increased renal tubular reabsorption of phosphate and
thus hyperphosphatemia. The result is typically calciﬁcation of the
entire body [5,6].
Erroneously, TC or Teutschlaender disease [7–9] have been
widely used in the literature to describe any massive collection
of peri-articular calciﬁcations. Though, most reported cases are in
fact secondary TC due to chronic renal insufﬁciency, hyperparathy-
roidism, or hypervitaminosis D [10]. Regardless of the etiology,
these two types of TC do not differ in their radiologic or histopatho-
logic presentations [11], but need to be diagnosed correctly to
initiate targeted and effective treatment.roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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sFig. 1. Preoperative appearance of the swollen left hip joint.
. Presentation of case
In 2011 a 19-year-old female with an acute renal insufﬁciency
ue to nephronophthisis presented herself with septic arthritis
f the left hip because of a shaldon catheter-related bloodstream
nfection. After hip resection arthroplasty and antibiotic cement
pacer implantation the patient received a total hip replacement
THR). After wound healing and 4 months of physical exercises, near
ormal range of motion (ROM) and good function were achieved.
hereafter, she was on hemodialysis three times per week because
f end-stage renal disease. Three years later, the patient returned
o our hospital with the complaint of severe pain in the left groin
nd lateral hip. Physical examination detected tenderness over
he left greater trochanter and the surgical scar. The whole left
eg was enormously swollen (Fig. 1). No symptoms of infection
ere found. Hip range of motion was normal. Blood tests revealed:
emoglobin 9.2 g/dl, creatinine 6.7 mg/dl, C reactive protein (CRP)
.7 mg/dl, white blood cells (WBC) 7.9/nl, calcium 2.78 mmol/l,
hosphate 6.3 mg/dl (2.5–5.0 mg/dl), calcium-phosphate serum
roduct 6.24 mmol2/l2 (0–4.4 mmol2/l2), intact parathyroid hor-
one (PTH) 779 ng/l (15–65 ng/l), 25-hydroxyvitamin D3 57 ng/ml
30–70 ng/ml). Rheumatoid factor and antinuclear antibody were
bsent. X-rays of the left hip and proximal upper limb revealed
ronounced peri-articular soft-tissue calciﬁcations similar to a
auliﬂower. Computed tomography (CT) scans demonstrated
morphous and multilobulated calciﬁed masses around the left hip
oin and in the region of the iliac muscle (Fig. 2a and b). Abdominal
rgans were normal. Bone scintigraphy with radiolabeled phos-
hate compounds (technetium—99 m methylene diphosphonate)
as performed to detect further lesions and found increased uptake
n the peri-articular soft-tissue of the left shoulder. The patient
eported a fall on the left shoulder several years ago. Standard radio-
raphy of the left shoulder revealed tumoral masses similar to the
nes described for the left hip joint (Fig. 3a). An incision biopsy
f the tumor located at the left hip joint was performed. During
urgery a white and yellow chalky substance (Fig. 4) appeared.PEN  ACCESS
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Microbiology of the biopsy was  sterile. Histopathologic evaluation
of the excised mass showed numerous psammoma  bodies with
inﬂammatory and histiocytic reaction.
Due to increased PTH level a parathyroid sestamibi scan was
initiated and revealed parathyroid hyperplasia of the caudal
right parathyroid gland. Additionally, a conciliar examination was
ordered. Ophthalmological examination revealed obvious conjunc-
tival calciﬁc deposits and retinal angioid streaks in both eyes.
Measurement of c-terminal ﬁbroblast growth factor (FGF)-23
was elevated (1345 kRU/l) (26–110 kRU/l). Thereupon, the patient
was screened for mutations in all exons of FGF23, GALNT3 and
KL. No mutations were found. A diagnosis of secondary TC was
made and a non-operative approach was  initially indicated. Her
medical treatments were changed toward decreasing intesti-
nal phosphate absorption and increasing phosphate excretion.
Calcium- and phosphate-restricted diets were started. The patient
was treated with Renagel® 1600 mg (Sevelamer hydrochlorid) and
OsvaRen® 435/235 mg  (Calcium diacetat x-Wasser, Magnesium
carbonat) (each taken three times a day) but serum phosphate lev-
els remained high. In the following, Mimpara® 60 mg  (Cinacalcet
hydrochlorid) (once a day) was prescribed and blood calcium levels
in the high normal range were achieved.
The initially conducted therapy of dietary deprivation of phos-
phate and phosphate-binding medication was not able to prevent
the progression of the calciﬁcations. Therefore, a sP (removing
3 1/2 glands) was performed. Three months after surgery, the
patient was free of complaints. In particular, she did not feel any
pain in the left hip or shoulder and her left leg was  only slightly
swollen. X-ray of the left shoulder and left hip revealed reduced
tumoral masses (Fig. 2c). Peri-articular soft-tissue calciﬁcations of
the left shoulder were barely visible (Fig. 3b). Although, the labo-
ratory proﬁle showed no changes with this development. Directly
after sP PTH level fell to 135 ng/l (preoperative: 779 ng/l) but four
days after surgery PTH concentration increased again to 533 ng/l.
Though, there was no evidence for ectopic parathyroid glands in
the neck or mediastinum. On order of a nephrologist we  discon-
tinued Mimpara® and OsvaRen® and started medical treatment of
Fosrenol® 1000 mg  (Lanthan(III) carbonat x-Wasser) (three times
a day).
3. Discussion
Calciﬁed masses near large joins were early on recognized and
described by Duret in 1899 [12]. Teutschländer [9] introduced the
term progressive lipocalcinogranulomatosis in 1935, while Alberto
in 1943 [13] proposed the current name tumoral calcinosis.
TC is an uncommon lesion that is either primary (heredi-
tary) or secondary to other diseases. The primary TC is caused
by autosomal recessive mutations in three genes involving phos-
phate metabolism, namely FGF23,  GALNT3 and KL [3]. Secondary
TC is associated with renal failure and prolonged hemodialysis.
Although, other conditions such as hyperparathyroidism, sarcoido-
sis, hypervitaminosis D and scleroderma have been reported to be
accompanied by TC [14]. Regardless of etiology, patients typically
present with progressively increasing tumor-like masses in peri-
articular locations. Patients often complain about localized swelling
and reduced mobility around the involved joints. Furthermore, cal-
cifying organ manifestation is typically found in eyes [6], as was
seen as well in our patient.
In renal secondary hyperparathyroidism, impaired renal phos-
phate elimination due to the reduced clearance function of the
kidneys is the reason for an increased phosphate concentration in
the serum. The inhibited renal synthesis of 1,25-dihydroxyvitamin
D leads to a reduced enteral calcium absorption. The resulting
hypocalcaemia leads to a stimulation of the parathyroid glands,
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Fig. 2. Standard x-ray (a) and CT scan (b) of the left hip and proximal upper limb before and after subtotal parathyroidectomy (c).
Fig. 3. Standard x-ray of the left shoulder before (a) and after subtotal parathyroidectomy (b).
CASE  REPORT  –  O
K.E. Niemann et al. / International Journal of 
Fig. 4. Intraoperative result: white and yellow chalky substance.
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[11] M.  Franco, L. Van Elslande, C. Passeron, J.F. Verdier, D. Barrillon, E.
Cassuto-Viguier, et al., Tumoral calcinosis in hemodialysis patients. A review
of  three cases, Rev. Rhumatisme Engl. Ed. 64 (1) (1997) 59–62.ncreasing PTH-level. PTH again, causes an osseous calcium mobi-
ization and thus leads to osteopenia. Additionally, the persisting
ow vitamin D level leads to a skeletal resistance to PTH, which
eans that hypocalcaemia cannot be compensated for, resulting
n increased PTH levels [15]. In renal failure patients an ele-
ated calcium-phosphate serum product explains the occurrence
f soft-tissue calciﬁcations. A calcium-phosphate serum product
5.8 mmol2/l2 may  lead to extraosseous calciﬁcations [16].
In the presented case, a young patient with secondary TC due
o secondary hyperparathyroidism as a result of end-stage renal
isease was treated. After sP a regression of the TC was observed.
hree months after surgery, the tumor around the left hip joint
howed a signiﬁcant decrease in size and radiographic appearance,
hereas a rapid complete regression of the tumoral masses around
he left shoulder was observed. We  thus complement the preceded
iterature.
In 1994, Benkert et al. [16] observed a regression up to com-
lete dissolution of TC after sP. Three years later, in 1997, a female
atient with end-stage renal failure and tumoral calciﬁcations in
he clavicular region was treated with total parathyroidectomy.
n this case TC disappeared after surgery [17]. Further, Cohen and
arikh performed a partial parathyroidectomy and achieved regres-
ion of tumoral calciﬁcations [18]. Moeckel et al. [15] treated two
enal failure patients with TC as a result of secondary hyperparathy-
oidism. After initial conservative therapy they performed a sP in
ne of the cases, after which a complete regression was  achieved.
he second patient obtained surgical excision of the foci, whereby
ocal recurrences were observed.
If TC is assumed, a biochemical proﬁle (including serum calcium
nd phosphate levels, serum PTH levels and 1,25-hydroxyvitamin
 levels) and renal function should be examined. Detailed family,
rug and past history should also be obtained. Without signs for a
rimary disease a screening for mutations in FGF23, GALNT3 and KL
ene should be considered. In case of a secondary TC an initial con-
ervative approach is indicated. Medical treatment includes the use
f phosphate binders, an optimization of dialysis and a phosphate
estricted diet. If this fails or the therapeutic outcome is unsatis-
actory, sP should be considered. In these patients surgical excision
r biopsies of the tumoral masses should be kept as a last resort
ecause of extensive complications (delayed wound healing, sec-
ndary infections, ﬁstula formation). Considering the primary TC,
rimary treatment is early and complete surgical excision [19]. Par-
ial excision of large lesions may  lead to pain relief but incomplete
xcision involves the risk of high recurrence rates or even faster
rowth [1,15,20].
[PEN  ACCESS
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4. Conclusion
The two types of TC need to be diagnosed correctly to initiate
the right treatment. Especially, in chronic kidney disease patients
with a secondary TC early sP may  be an approach to treatment to
avoid prolonged suffering and potential mutilations.
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